Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.66 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.66 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.66 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.66 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.66 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286583 | 0.85 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL310492 | 0.79 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1642920 | 0.79 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL310470 | 0.79 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1643466 | 0.77 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2539835 | 0.77 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL638589 | 0.77 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL310019 | 0.76 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL29392347 | 0.76 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Avagacestat SCHEMBL381851 | 0.76 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419090-A1 | BIOAVAILABLE CAPSULE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | Bristol-Myers Squibb Company (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010120755-A1 | BIOAVAILABLE CAPSULE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | claimed |
| EP-2408450-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010120755-A1 | BIOAVAILABLE CAPSULE COMPOSITIONS OF AMORPHOUS ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010107435-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |